Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: A clinical, epidemiological and therapeutic assessment

Current Opinion in Rheumatology

Volumn 26, Issue 4, 2014, Pages 377-383

  Poddubnyy, Denis ^a   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ankylosing spondylitis; clinical manifestations; epidemiology; nonradiographic axial spondyloarthritis; therapy; treatment

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; DISEASE ACTIVITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; SACROILIAC JOINT; SPONDYLARTHRITIS; TREATMENT RESPONSE;

EID: 84901845023     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000071     Document Type: Review

References (52)

1. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68:777-783. [Epub 2009/03/20]
2. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361-368. (Pubitemid 14134775)
3. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005; 52:1000-1008. (Pubitemid 40530105)
4. Sampaio-Barros PD, Bertolo MB, Kraemer MH, et al. Undifferentiated spondy-loarthropathies: a 2-year follow-up study. Clin Rheumatol 2001; 20:201-206. (Pubitemid 32586566)
5. Sampaio-Barros PD, Bortoluzzo AB, Conde RA, et al. Undifferentiated spon-dyloarthritis: a longterm followup. J Rheumatol 2010; 37:1195-1199. [Epub 2010/05/04]
6. Schattenkirchner M, Kruger K. Natural course and prognosis of HLA-B27-positive oligoarthritis. Clin Rheumatol 1987; 6 (Suppl 2):83-86.
7. Sany J, Rosenberg F, Panis G, Serre H. Unclassified HLA-B27 inflammatory rheumatic diseases: followup of 23 patients. Arthritis Rheum 1980; 23:258-259. [Epub 1980/02/01]
8. Huerta-Sil G, Casasola-Vargas JC, Londono JD, et al. Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloar-thritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. Ann Rheum Dis 2006; 65:642-646.
9. Mau W, Zeidler H, Mau R, et al. Outcome of possible ankylosing spondylitis in a 10years' follow-up study. Clin Rheumatol 1987; 6 (Suppl 2):60-66.
10. Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radio-graphic sacroiliitis progression over 2 years in patients with axial spondyloar-thritis. Ann Rheum Dis 2011; 70:1369-1374. [Epub 2011/05/31]
11. Bennett AN, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008; 58:3413-3418. [Epub 2008/11/01]
12. Gofton JP, Robinson HS, Trueman GE. Ankylosing spondylitis in a Canadian Indian population. Ann Rheum Dis 1966; 25:525-527.
13. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984; 27:241-249. (Pubitemid 14163215)
14. Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995; 7:263-269.
15. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41:58-67. (Pubitemid 28041923)
16. Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 inthe United States. Am J Med Sci 2013; 345:431-436. [Epub 2013/07/11]
17. Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001; 28:554-559. [Epub 2001/04/12] (Pubitemid 32202659)
18. Belachew DA, Sandu N, Schaller B, Guta Z. Ankylosing spondylitis in sub-Saharan Africa. Postgrad Med J 2009; 85:353-357. [Epub 2009/07/08]
19. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58:15-25. [Epub 2008/01/01]
20. Strand V, Rao SA, Shillington AC, et al. Prevalence of axial spondyloarthritis in United States rheumatology practices: assessment of Spondylo Arthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (Hoboken) 2013; 65:1299-1306. [Epub 2013/02/26]
21. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60:717-727.
22. Kiltz U, Baraliakos X, Karakostas P, et al. Do patients with nonradiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012; 64:1415-1422. [Epub 2012/04/17]
23. Ciurea A, Scherer A, Exer P, et al. Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013; 65:3096-3106. [Epub 2013/08/29]
24. Song IH, Weiss A, Hermann KG, et al. Similar response rates in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013; 72:823-825. [Epub 2012/11/23]
25. Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 2014; 73:39-47. [Epub 2013/09/10]
26. Brandt HC, Spiller I, Song IH, et al. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007; 66:1479-1484. [Epub 2007/04/26] (Pubitemid 350032656)
27. Poddubnyy D, Vahldiek J, Spiller I, et al. Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol 2011; 38:2452-2460.
28. Poddubnyy D, Brandt H, Vahldiek J, et al. The frequency of nonradiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. Ann Rheum Dis 2012; 71:1998-2001. [Epub 2012/08/24]
29. Sieper J, Srinivasan S, Zamani O, et al. Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis 2013; 72:1621-1627. [Epub 2012/10/16]
30. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach todefining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21:2286-2291.
31. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21:2281-2285.
32. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21:1694-1698. (Pubitemid 24285485)
33. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spon-dylitis patient advocacy groups. Curr Opin Rheumatol 2000; 12:239-247. [Epub 2000/07/26] (Pubitemid 30439674)
34. Dougados M, d'Agostino MA, Benessiano J, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine 2011; 78:598-603. [Epub 2011/04/05]
35. van den Berg R, de Hooge M, van Gaalen F, et al. Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology (Oxford) 2013; 52:1492-1499. [Epub 2013/05/08]
36. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896-904. [Epub 2011/05/05]
37. Van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:905-908. [Epub 2011/05/05]
38. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondy-loarthritis: results from the double-blind, placebo-controlled INFAST study, part 1. Ann Rheum Dis 2014; 73:101-107. [Epub 2013/05/23]
39. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44:1876-1886. [Epub 2001/08/18] (Pubitemid 32758236)
40. Sieper J, Rudwaleit M, Lenaerts J, et al. Role of baseline C-reactive protein in response to infliximab plus naproxen vs naproxen alone in patients with axial spondyloarthritis inthe INFAST study. Ann Rheum Dis 2013;72(Suppl 3):518.
41. Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondy-litis. Ann Rheum Dis 2004; 63:1438-1444. [Epub 2004/03/27] (Pubitemid 39433948)
42. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582-591. [Epub 2005/02/05] (Pubitemid 40216323)
43. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136-2146. [Epub 2006/06/28] (Pubitemid 44051069)
44. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005; 64:1557-1562. (Pubitemid 41532037)
45. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-3412. [Epub 2008/11/01]
46. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondy-litis. Ann Rheum Dis 2004; 63:665-670. (Pubitemid 38658395)
47. Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60:946-954. [Epub 2009/04/01]
48. Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasa-lazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011; 70:590-596. [Epub 2011/03/05]
49. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58:1981-1991. [Epub 2008/06/26] (Pubitemid 351988090)
50. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013; 72:815-822. [Epub 2012/07/10]
51. Dougados M, van der Heijde D, Sieper J, et al. Clinical and imaging efficacy of etanercept in early nonradiographic axial spondyloarthritis; a 12-week, randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2013; 72 (Suppl):87.
52. Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2010; 70:47-53. [Epub 2010/11/12]